While market conditions are still keeping the IPO window mostly closed, the year's large issuers are finding support, especially over the past few months. Excluding high-flying outlier HKD, just 15 IPOs have raised $100 million or more in 2022, and 13 (87%)...read more
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
In February, eight IPOs raised $271 million, a 76% y/y decline in IPO count and a 97% drop in proceeds. February IPOs raised fewer proceeds than any month since November 2018. The month’s issuers were primarily micro-caps, as the average deal size shrank...read more
The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings. CAR-T biotech Arcellx (ACLX) priced at the low end to...read more
Nearly 90% of 2022's large IPOs are trading above issue
While market conditions are still keeping the IPO window mostly closed, the year's large issuers are finding support, especially over the past few months. Excluding high-flying outlier HKD, just 15 IPOs have raised $100 million or more in 2022, and 13 (87%)...read more
Biotech IPOs struggle to tread water amid challenging market conditions
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
Renaissance Capital's February IPO Market Update
In February, eight IPOs raised $271 million, a 76% y/y decline in IPO count and a 97% drop in proceeds. February IPOs raised fewer proceeds than any month since November 2018. The month’s issuers were primarily micro-caps, as the average deal size shrank...read more
US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs
The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings. CAR-T biotech Arcellx (ACLX) priced at the low end to...read more